Among the ICIs, PD-1/PD-L1 and CTLA-4 inhibitors have exhibited encouraging therapeutic outcomes, and some have been indicated for various tumor treatments since 2011 (Table 1), whereas others are under clinical trials [26]. This evidence concerns the gene CTLA4 and neoplasm.